TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

HEPARIN SODIUM
Cardiovascular Approved 1972-02-22
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
3
Indications
--
Phase 3 Trials
54
Years on Market

Details

Status
Prescription
First Approved
1972-02-22
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Fresenius Kabi Pfizer
Active Ingredient: HEPARIN SODIUM

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% Approval History

Loading approval history...

What HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% Treats

6 indications

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% is approved for 6 conditions since its original approval in 1972. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Venous Thrombosis
  • Pulmonary Embolism
  • Deep Venous Thrombosis
  • Atrial Fibrillation
  • Disseminated Intravascular Coagulation
  • Peripheral Arterial Embolism
Source: FDA Label

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% Target & Pathway

Pro

Target

FACTOR XA (Coagulation Factor Xa) Coagulation Factor

A key enzyme in the blood clotting cascade that converts prothrombin to thrombin. Inhibiting Factor Xa prevents clot formation, reducing risk of stroke in atrial fibrillation and treating/preventing venous thromboembolism.

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% Competitors

Pro

10 other drugs also target FACTOR XA. Compare mechanisms, indications, and trial activity.

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Pfizer
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Pfizer
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Pfizer
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Pfizer
RIVAROXABAN
TARO
ELIQUIS
Bristol-Myers Squibb
ELIQUIS SPRINKLE
Bristol-Myers Squibb
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%
Fresenius Kabi
View all 10 FACTOR XA drugs →
Drug = Competitor name Company = Manufacturer N indic. = FDA-approved indications → Date = Patent/exclusivity expiry

Competitors share the same molecular target (FACTOR XA). Earlier expiry dates signal biosimilar/generic opportunities.

Drugs Similar to HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HEPARIN SODIUM
6 shared
Baxter
Shared indications:
Venous ThrombosisPulmonary EmbolismDeep Venous Thrombosis +3 more
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HEPARIN SODIUM
6 shared
Pfizer
Shared indications:
Venous ThrombosisPulmonary EmbolismDeep Venous Thrombosis +3 more
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
HEPARIN SODIUM
6 shared
Pfizer
Shared indications:
Venous ThrombosisPulmonary EmbolismDeep Venous Thrombosis +3 more
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
HEPARIN SODIUM
6 shared
Pfizer
Shared indications:
Venous ThrombosisPulmonary EmbolismDeep Venous Thrombosis +3 more
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HEPARIN SODIUM
6 shared
Baxter
Shared indications:
Venous ThrombosisPulmonary EmbolismDeep Venous Thrombosis +3 more
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%
HEPARIN SODIUM
6 shared
Fresenius Kabi
Shared indications:
Venous ThrombosisPulmonary EmbolismDeep Venous Thrombosis +3 more
HEPARIN SODIUM IN PLASTIC CONTAINER
HEPARIN SODIUM
6 shared
Fresenius Kabi
Shared indications:
Venous ThrombosisPulmonary EmbolismDeep Venous Thrombosis +3 more
JANTOVEN
WARFARIN SODIUM
3 shared
UPSHER SMITH LABS
Shared indications:
Venous ThrombosisPulmonary EmbolismAtrial Fibrillation
DABIGATRAN ETEXILATE MESYLATE
DABIGATRAN ETEXILATE MESYLATE
2 shared
HETERO LABS LTD III
Shared indications:
Atrial FibrillationPulmonary Embolism
ELIQUIS
APIXABAN
2 shared
Bristol-Myers Squibb
Shared indications:
Atrial FibrillationPulmonary Embolism
ELIQUIS SPRINKLE
APIXABAN
2 shared
Bristol-Myers Squibb
Shared indications:
Atrial FibrillationPulmonary Embolism
SAVAYSA
EDOXABAN TOSYLATE
2 shared
DAIICHI SANKYO INC
Shared indications:
Atrial FibrillationPulmonary Embolism
ACTIVASE
ALTEPLASE
1 shared
Roche
Shared indications:
Pulmonary Embolism
ARIXTRA
FONDAPARINUX SODIUM
1 shared
Viatris
Shared indications:
Pulmonary Embolism
BETAPACE
SOTALOL HYDROCHLORIDE
1 shared
LEGACY PHARMA
Shared indications:
Atrial Fibrillation
BREVIBLOC
ESMOLOL HYDROCHLORIDE
1 shared
Baxter
Shared indications:
Atrial Fibrillation
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
ESMOLOL HYDROCHLORIDE
1 shared
Baxter
Shared indications:
Atrial Fibrillation
BREVIBLOC IN PLASTIC CONTAINER
ESMOLOL HYDROCHLORIDE
1 shared
Baxter
Shared indications:
Atrial Fibrillation
CORVERT
IBUTILIDE FUMARATE
1 shared
Pfizer
Shared indications:
Atrial Fibrillation
DOFETILDE
DOFETILIDE
1 shared
Aurobindo Pharma
Shared indications:
Atrial Fibrillation
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Heparin Sodium Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA017029 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.